Alnylam Pharmaceuticals reported $283.77M in Gross Profit on Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US USD 134.08M 5.5M
Agios Pharmaceuticals AGIO:US USD 3.9M 898K
Alnylam Pharmaceuticals ALNY:US USD 283.77M 60.58M
Amgen AMGN:US USD 5.09B 28M
Biocryst Pharmaceuticals BCRX:US USD 77.05M 4.84M
Biomarin Pharmaceutical BMRN:US USD 410.25M 21.19M
Bluebird Bio BLUE:US USD 71K 297K
Intercept Pharmaceuticals ICPT:US USD 77.19M 27K
Moderna Inc MRNA:US USD 3.17B 902M
Neurocrine Biosciences NBIX:US USD 404.3M 22.5M
Novartis NVS:US USD 9.16B 21M
Ptc Therapeutics PTCT:US USD 156.52M 46.6M
Regeneron Pharmaceuticals REGN:US USD 2.87B 255.4M
Sarepta Therapeutics SRPT:US USD 227.63M 37.31M
Takeda 4502:JP JPY 760.58B 63.72B
Ultragenyx Pharmaceutical RARE:US USD 98.03M 15.96M
Vertex Pharmaceuticals VRTX:US USD 2.02B 25.5M
YTE INCY:US USD 872.94M 98.92M